Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Nov;39(11):2585–2587. doi: 10.1128/aac.39.11.2585

Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.

T I Nicas 1, D L Mullen 1, J E Flokowitsch 1, D A Preston 1, N J Snyder 1, R E Stratford 1, R D Cooper 1
PMCID: PMC162992  PMID: 8585753

Abstract

LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin-resistant enterococci of < or = 4 micrograms/ml for 50% of isolates and < or = 16 micrograms/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 micrograms/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic-resistant gram-positive bacteria.

Full Text

The Full Text of this article is available as a PDF (196.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernareggi A., Cavenaghi L., Assandri A. Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose. Antimicrob Agents Chemother. 1986 Nov;30(5):733–738. doi: 10.1128/aac.30.5.733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chin N. X., Neu H. C. In vitro activity of LY264826 compared to other glycopeptides and daptomycin. Diagn Microbiol Infect Dis. 1991 Mar-Apr;14(2):181–184. doi: 10.1016/0732-8893(91)90056-l. [DOI] [PubMed] [Google Scholar]
  3. Courvalin P. Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother. 1990 Dec;34(12):2291–2296. doi: 10.1128/aac.34.12.2291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Handwerger S., Raucher B., Altarac D., Monka J., Marchione S., Singh K. V., Murray B. E., Wolff J., Walters B. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis. 1993 Jun;16(6):750–755. doi: 10.1093/clind/16.6.750. [DOI] [PubMed] [Google Scholar]
  5. Johnson A. P., Uttley A. H., Woodford N., George R. C. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin Microbiol Rev. 1990 Jul;3(3):280–291. doi: 10.1128/cmr.3.3.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Leclercq R., Derlot E., Weber M., Duval J., Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 1989 Jan;33(1):10–15. doi: 10.1128/aac.33.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Nagarajan R., Berry D. M., Schabel A. A. The structural relationships of A82846B and its hydrolysis products with chloroorienticins A, B and C. J Antibiot (Tokyo) 1989 Sep;42(9):1438–1440. doi: 10.7164/antibiotics.42.1438. [DOI] [PubMed] [Google Scholar]
  8. Nagarajan R., Schabel A. A., Occolowitz J. L., Counter F. T., Ott J. L., Felty-Duckworth A. M. Synthesis and antibacterial evaluation of N-alkyl vancomycins. J Antibiot (Tokyo) 1989 Jan;42(1):63–72. doi: 10.7164/antibiotics.42.63. [DOI] [PubMed] [Google Scholar]
  9. Nagarajan R., Schabel A. A., Occolowitz J. L., Counter F. T., Ott J. L. Synthesis and antibacterial activity of N-acyl vancomycins. J Antibiot (Tokyo) 1988 Oct;41(10):1430–1438. doi: 10.7164/antibiotics.41.1430. [DOI] [PubMed] [Google Scholar]
  10. Nagarajan R. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiot (Tokyo) 1993 Aug;46(8):1181–1195. doi: 10.7164/antibiotics.46.1181. [DOI] [PubMed] [Google Scholar]
  11. Nicas T. I., Cole C. T., Preston D. A., Schabel A. A., Nagarajan R. Activity of glycopeptides against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother. 1989 Sep;33(9):1477–1481. doi: 10.1128/aac.33.9.1477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Noble W. C., Virani Z., Cree R. G. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 1992 Jun 1;72(2):195–198. doi: 10.1016/0378-1097(92)90528-v. [DOI] [PubMed] [Google Scholar]
  13. Perl T. M., Wenzel R. P., Jones R. N. In-vitro activity of LY264826, an investigational glycopeptide antibiotic, against gram-positive bloodstream isolates and selected gram-negative bacilli. J Antimicrob Chemother. 1992 May;29(5):596–598. doi: 10.1093/jac/29.5.596. [DOI] [PubMed] [Google Scholar]
  14. Rolston K. V., Nguyen H., Messer M. In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer. Antimicrob Agents Chemother. 1990 Nov;34(11):2137–2141. doi: 10.1128/aac.34.11.2137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Uttley A. H., Collins C. H., Naidoo J., George R. C. Vancomycin-resistant enterococci. Lancet. 1988 Jan 2;1(8575-6):57–58. doi: 10.1016/s0140-6736(88)91037-9. [DOI] [PubMed] [Google Scholar]
  16. Watanakunakorn C. Comparison of LY264826-gentamicin with vancomycin-gentamicin against enterococci from blood cultures. J Antimicrob Chemother. 1992 Mar;29(3):303–306. doi: 10.1093/jac/29.3.303. [DOI] [PubMed] [Google Scholar]
  17. Williamson R., Al-Obeid S., Shlaes J. H., Goldstein F. W., Shlaes D. M. Inducible resistance to vancomycin in Enterococcus faecium D366. J Infect Dis. 1989 Jun;159(6):1095–1104. doi: 10.1093/infdis/159.6.1095. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES